Oura filed a public S-1 on September 3 for an initial public offering on the Nasdaq Global Select Market under the ticker OURA. The smart ring maker reported $1.21 billion in revenue for the nine months ended June 30, 2026. That is up 74 percent from $697.6 million a year earlier. Net income was $60.8 million, against $1.6 million. Share count and price are not set.
Hardware brought in $974.0 million of that revenue and memberships $240.5 million. Oura sold 3.1 million rings in the period, up from 1.8 million, and ended it with 5.0 million paid members, double the prior year. Revenue for fiscal 2025, which ended September 30, 2025, was $907.9 million. Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen & Company and Jefferies lead the underwriting.
The regulatory posture is the part for device founders to read. Oura says it markets certain products and features as general wellness products. In the filing's words, it believes those are "not actively subject to the medical device regulatory requirements" of FDA. The S-1 lists no clearances. Blood pressure stays on the study side of that line. Oura says more than 350,000 members had enrolled in its investigational blood pressure profile study as of June 30. Whoop shipped a blood pressure feature and drew a warning letter in July 2025. FDA closed that letter in June after revising its general wellness guidance.
Oura redomiciled from Finland to Delaware on March 31, 2026 and lists its principal office at 415 Kearny Street in San Francisco. The filing also describes a glucose feature that pulls readings from Dexcom's Stelo biosensor through a direct integration. The regulated sensor belongs to someone else.